Knight Therapeutics Inc.

TSX:GUD Stock Report

Market Cap: CA$576.7m

Knight Therapeutics Management

Management criteria checks 3/4

Knight Therapeutics' CEO is Samira Sakhia, appointed in Aug 2016, has a tenure of 8.42 years. total yearly compensation is CA$1.33M, comprised of 38.6% salary and 61.4% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth CA$1.62M. The average tenure of the management team and the board of directors is 3.6 years and 8.4 years respectively.

Key information

Samira Sakhia

Chief executive officer

CA$1.3m

Total compensation

CEO salary percentage38.6%
CEO tenure8.4yrs
CEO ownership0.3%
Management average tenure3.6yrs
Board average tenure8.4yrs

Recent management updates

Recent updates

Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 09
Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07
Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20
Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07
The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

CEO Compensation Analysis

How has Samira Sakhia's remuneration changed compared to Knight Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$31m

Jun 30 2024n/an/a

-CA$21m

Mar 31 2024n/an/a

-CA$17m

Dec 31 2023CA$1mCA$514k

-CA$17m

Sep 30 2023n/an/a

-CA$8m

Jun 30 2023n/an/a

-CA$16m

Mar 31 2023n/an/a

-CA$15m

Dec 31 2022CA$1mCA$468k

-CA$30m

Sep 30 2022n/an/a

-CA$23m

Jun 30 2022n/an/a

-CA$33m

Mar 31 2022n/an/a

-CA$7m

Dec 31 2021CA$1mCA$401k

CA$16m

Sep 30 2021n/an/a

CA$32m

Jun 30 2021n/an/a

CA$59m

Mar 31 2021n/an/a

CA$47m

Dec 31 2020CA$688kCA$298k

CA$42m

Sep 30 2020n/an/a

CA$27m

Jun 30 2020n/an/a

CA$6m

Mar 31 2020n/an/a

CA$8m

Dec 31 2019CA$987kCA$287k

CA$15m

Sep 30 2019n/an/a

CA$21m

Jun 30 2019n/an/a

CA$37m

Mar 31 2019n/an/a

CA$22m

Dec 31 2018CA$787kCA$267k

CA$24m

Compensation vs Market: Samira's total compensation ($USD923.19K) is about average for companies of similar size in the Canadian market ($USD1.14M).

Compensation vs Earnings: Samira's compensation has increased whilst the company is unprofitable.

CEO

Samira Sakhia (56 yo)

8.4yrs

Tenure

CA$1,331,900

Compensation

Ms. Samira Sakhia, MBA, BCom, CPA, CA, has been the President at Knight Therapeutics Inc. since August 31, 2016 and served as its Chief Financial Officer since October 10, 2017 until March 30, 2020. She ha...

Leadership Team

NamePositionTenureCompensationOwnership
Jonathan Goodman
Executive Chairman12yrsCA$490.55k21.7%
CA$ 125.2m
Samira Sakhia
President8.4yrsCA$1.33m0.28%
CA$ 1.6m
Arvind Utchanah
Chief Financial Officer4.8yrsCA$869.82k0.043%
CA$ 249.2k
Amal Khouri
Chief Business Officer3.8yrsCA$839.55k0.16%
CA$ 921.1k
Stephani Saverio
Vice President of Business Development3.8yrsCA$629.57kno data
Leopoldo Bosano
Vice-President of Manufacturing & Operations2.8yrsno datano data
Henrique Dias
Global Director of Marketing2yrsno data0.0032%
CA$ 18.2k
Susan Emblem
Global Vice President of Human Resources3.4yrsno data0.022%
CA$ 128.4k
Jeff Martens
Global Vice President of Commercial4.3yrsCA$534.15kno data
Melanie Groleau
Global Vice President of Medical & Clinical1yrno data0.0030%
CA$ 17.5k

3.6yrs

Average Tenure

Experienced Management: GUD's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jonathan Goodman
Executive Chairman12yrsCA$490.55k21.7%
CA$ 125.2m
Samira Sakhia
President8.4yrsCA$1.33m0.28%
CA$ 1.6m
James Gale
Independent Lead Director12yrsCA$155.00k0.052%
CA$ 301.3k
Robert Lande
Independent Director11yrsCA$127.50k0.24%
CA$ 1.4m
Nicolas Sujoy
Independent Director4.6yrsCA$132.43k0.012%
CA$ 67.9k
Janice Murray
Independent Director4.6yrsCA$122.50k0.0089%
CA$ 51.6k
Michael Tremblay
Independent Director5.7yrsCA$115.00k0.0020%
CA$ 11.5k

8.4yrs

Average Tenure

58yo

Average Age

Experienced Board: GUD's board of directors are considered experienced (8.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/29 11:33
End of Day Share Price 2025/01/29 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Knight Therapeutics Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David KideckelBeacon Securities Limited
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity